Abstract: A motor driven power steering system includes: a power source for generating a steering assistance force assisting the steering of a vehicle; a transfer gear positioned between a power source and a column for transferring the steering assistance force generated by the power source to the column; a parameter estimation unit for estimating a friction parameter of a dynamic friction model based on the actual friction torque actually generated in the transfer gear; and a state estimation unit for calculating a state variable of the dynamic friction model based on a contact surface moving speed of the transfer gear and for estimating expected friction torque according to the dynamic friction model by using the calculated state variable and the friction parameter of the dynamic friction model estimated by the parameter estimation unit.

Abstract: A control system for operating an air vehicle for urban air mobility (UAM) is arranged such that when a steering operation for a steering wheel and a stroke operation for an accelerator pedal and a brake pedal are performed for operating the air vehicle for UAM, haptic feedback providing notification of any operational limitations is provided to a driver, so that operation stability and convenience of the driver are secured and stable steering, acceleration, and deceleration of the air vehicle are performed.

Abstract: A system and method for detecting a hands-off state of a steering wheel may include acquiring, by a controller, a steering torque, a steering angle and a steering angular speed while driving of a vehicle, determining, by the controller, a variance value of the steering angular speed through cumulation for a designated time, determining, by the controller, a difference value between a steering angular speed estimated through a steering system model determined on an assumption that the steering wheel is in the hands-off state and a measured steering angular speed through cumulation for a designated time, when the variance value of the steering angular speed is less than a first threshold value, and divisionally determining, by the controller, whether or not the steering wheel is in the hands-off state or in the hands-on state according to the difference value between the measured and estimated steering angular speeds.

Abstract: A motor driven power steering system includes: a power source for generating a steering assistance force assisting the steering of a vehicle; a transfer gear positioned between a power source and a column for transferring the steering assistance force generated by the power source to the column; a parameter estimation unit for estimating a friction parameter of a dynamic friction model based on the actual friction torque actually generated in the transfer gear; and a state estimation unit for calculating a state variable of the dynamic friction model based on a contact surface moving speed of the transfer gear and for estimating expected friction torque according to the dynamic friction model by using the calculated state variable and the friction parameter of the dynamic friction model estimated by the parameter estimation unit.

Abstract: Disclosed is an electronic device.

Abstract: A system and method for detecting a hands-off state of a steering wheel may include acquiring, by a controller, a steering torque, a steering angle and a steering angular speed while driving of a vehicle, determining, by the controller, a variance value of the steering angular speed through cumulation for a designated time, determining, by the controller, a difference value between a steering angular speed estimated through a steering system model determined on an assumption that the steering wheel is in the hands-off state and a measured steering angular speed through cumulation for a designated time, when the variance value of the steering angular speed is less than a first threshold value, and divisionally determining, by the controller, whether or not the steering wheel is in the hands-off state or in the hands-on state according to the difference value between the measured and estimated steering angular speeds.

Abstract: Disclosed is an electronic device.

Abstract: A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1?, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

Abstract: A compound inhibiting Hsp90 and a pharmaceutical composition including the same as an active ingredient are described, which compound is represented by formula 2 and suppresses the expression of Hsp90, inhibits the accumulation of HIF-1?, the Hsp90 client protein, and efficiently inhibits the activation of VEGF. The compound displays low cytotoxicity and can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.

Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.

Abstract: The present invention relates to a compound inhibiting Hsp90 and a pharmaceutical composition comprising the same as an active ingredient. The compounds represented by formula 1 and formula 2 of the present invention suppress the expression of Hsp90 so that they can inhibit the accumulation of HIF-1?, the Hsp90 client protein, and also efficiently inhibit the activation of VEGF. In addition, these compounds display low cytotoxicity, so that they can be effectively used as an active ingredient of an anti-cancer agent, a diabetic retinopathy treating agent, and an anti-arthritic agent.

Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.

Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.

Abstract: The invention includes a pharmaceutical composition comprising an expression or activity regulator of AKAP12 (A-kinase anchoring protein 12) as the active ingredient. The compositions of the invention are useful for treating central nervous system diseases. The invention further includes a method of treating central nervous system diseases using a pharmaceutical composition of the invention. The central nervous system diseases contemplated within the invention include post-traumatic stress syndrome, stroke, and spinal injury.

Abstract: Provided is a method of defending against a battery exhaustion attack on a wireless communication device. The method includes: determining whether a battery exhaustion attack against a first wireless communication device occurred based on a connection state between the first wireless communication device and at least one second wireless communication device; if it is determined to be a battery exhaustion attack against the first wireless communication device, defending the battery exhaustion attack using a communication module of the first wireless communication device; and if it is determined that the is no a battery exhaustion attack against the first wireless communication device, performing communication between the first wireless communication device and the at least one second wireless communication device according to the connection state.

Abstract: Provided is a system for providing a silent advertisement that includes a multimedia message server for generating a multimedia message containing at least one piece of silent advertisement data and transmitting the multimedia message to an arbitrary mobile terminal, and the mobile terminal for receiving the multimedia message, detecting and storing the silent advertisement data contained in the multimedia message without notifying a user, and if a current operational state of the mobile terminal corresponds to a pre-set silent advertisement output condition, outputting the silent advertisement data. Accordingly, provided is a method, apparatus, and system for silently transmitting advertisement data to a mobile terminal of a user even if the user does not request to receive advertisements in advance, which are used by a communication provider to modify advertisement data stored in advance in the mobile terminal of the user in response to a request of a sponsor.

Abstract: Provided is an operating voltage scaling method for a portable terminal. The method includes, if reproduction of a moving image is requested, acquiring DYNamicity (DYN) of the reproduction-requested moving image, determining whether frame skipping is possible for the moving image according to the acquired DYN of the moving image, and if it is determined that frame skipping is possible for the moving image, supplying a low operating voltage to a controller of the mobile terminal to control the mobile terminal to operate with a low-speed clock, and reproducing the moving image while skipping a frame.

Abstract: The present invention relates to a composition comprising a Ninjurin1 expression or activity inhibitor for the prevention and treatment of inflammatory disease. Ninjurin1 protein is specifically expressed in macrophages around blood vessels, increases cell-cell adhesion and cell-matrix adhesion, increases expressions of Wnt7b (Wingless-type MMTV integration site family, member 7B) and Ang2 (angiopoietin-2), but reduces expression of Ang1 to induce apoptosis of vascular endothelial cells. In addition, Ninjurin1 protein is up-regulated when inflammation is induced and induces iNOS expression as well as increased NO generation. Therefore, the Ninjurin1 protein expression or activation inhibitor can be effectively used as an active ingredient of a composition for the prevention and treatment of inflammatory disease.

Abstract: Provided are a method of diagnosing the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and a method of screening a drug for preventing the recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery and treating hepatocellular carcinoma. Specifically, the recurrence or possibility of recurrence of hepatocellular carcinoma after hepatocellular carcinoma surgery is diagnosed and a drug for preventing the recurrence of hepatocellular carcinoma after surgery and treating hepatocellular carcinoma is screened, by measuring expression levels of a metastatic tumor antigen 1 or metastasis associated 1 (MTA1) protein in a biological sample taken from a patient in which hepatocellular carcinoma recurs or is likely to recur after hepatocellular carcinoma surgery and comparing the measured expression levels of the MTA1 protein with those of a normal control group.